FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> software | Medidata | Drug Safety

Safety reporting tool leads Medidata to strong 2009

Free Newsletter

FierceBiotech IT updates senior biotech, pharma, and IT leaders on how IT advances are shaping clinical trials and clinical research. Get your weekly briefing on clinical trial design and management systems, adaptive trials, eClinical trials, and more. Sign up today!



Tools

Trial-design, site-contracting, and safety-reporting tools are behind the 33 percent growth that solutions provider Medidata realized in 2009. President Glen de Vries says in an interview that product cross-selling and the fourth-quarter debut of the Rave Safety Gateway are major drivers.

Cross-sell efforts based on the company's Rave platform boosted sales of Medidata Designer, a protocol authoring tool. Four customers began piloting the system in the fourth quarter. Existing customers are also adding Rave Grants Manager software for site contract negotiations; two Rave customers began pilots in Q4.

De Vries says customers are asking how many separate trial-function systems Rave can replace. "That's evidence to us that the industry is changing."

The company launched the Rave Safety Gateway extension in December, aimed at simplifying safety event reporting. It allows a sponsor's legacy safety reporting systems to use data already collected and cleaned in Rave, streamlining the process of preparing data for submission. "Safety Gateway came from the fact that customers are looking for efficiency in the safety hand-off--in the reconciliation of trial and safety data." says de Vries.

Heightened FDA interest in safety, as witnessed by the regulator's increasing requirement for risk evaluation and mitigation strategies, is driving demand for safety tools. "REMS requirements are similar to what's been happening in Japan for years," he says. "We've been doing post-market studies there that are just like REMS studies. Sponsors want information structured in forms, but they need flexibility."

-  here's the financials release

Related Articles:
Unified takes on integrated in e-clinical systems
Medidata plans Mass. blitz
Supplier focus is interoperability


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotechIT Email Newsletter:

More stories about software   Medidata   Drug Safety